Ultrastructural study of anti-tumor effects of tamoxifen in two malignant melanoma patients

Journal of Dermatology

Volumn 24, Issue 7, 1997, Pages 441-450

  Hirota, Toru ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Estrogen receptor; Malignant melanoma; Metastasis; Tamoxifen; Ultrastructure

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CASE REPORT; CELL ULTRASTRUCTURE; DOSE RESPONSE; DRUG MECHANISM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOMA; SKIN NECROSIS;

EID: 0030853354     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.1997.tb02818.x     Document Type: Article

References (21)

1. Jimbo K (ed): Malignant Melanoma. Basic and Clinical Features, Fuji Shoin, Sapporo, Japan, 1987, pp 43-88.
2. Ishihara K, Yamazaki N: Color Atlas of Skin Tumors, Kanehara Shuppan, Tokyo, 1992, pp 359-369.
3. Nakajima T, Ishihara K: Pigmental Tumor, Bunkodo, Tokyo, 1993, pp 208-214.
4. Jimbow K: Skin Cancer, Medical View, Tokyo, 1988, pp 140-144.
5. Tan D, Gu Z, Wang H: The effect of estrogen and its receptor antagonist on the growth of human gastric cancer cell line in vitro, Chinese J of Oncology, 17: 93-96, 1995.
6. Farinati F: Tamoxifen treatment in hepatocellular carcinoma, Gastroenterology, 111: 272-274, 1996.
7. Mouridsen H, Palshof T, Patterson J, Battersby L: Tamoxifen in advanced breast cancer, Cancer Treatment Reviews, 5: 131-141, 1978.
8. Kiang DT, Kennedy BJ: Tamoxifen (antiestrogen) therapy in advanced breast cancer, Ann Intern Med, 87: 687-690, 1977.
9. Legha SS, Davis HL, Muggia FM: Hormonal therapy of breast cancer: New approaches and concept, Ann Intern Med, 88: 69-77, 1978.
10. Mouridsen H, Palshof T, Patterson J, Battersby L: Tamoxifen in advanced breast cancer, Cancer Treat Reviews, 5: 131-141, 1978.
11. Reddel RR, Murphy LC, Sutherland RL: Effects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cells in vitro, Cancer Res, 43: 4618-4624, 1983.
12. Sutherland RL, Hall RE, Taylor IW: Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau phase cells. Cancer Res, 43: 3998-4006, 1983.
13. Sutherland RL, Green MD, Hall RE, Reddel RR, Taylor IW: Tamoxifen induces accumulation of MCF-7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle, Eur J Cancer Clin Oncol, 19: 615-621, 1983.
14. Cocconi G, Bella M, Calabresi F, et al: Treatment of metastatic malignant melanoma with dacarubazine plus tamoxifen, N Engl J Med, 327: 516-523, 1992.
15. Creagan ET, Ingle JN, Green SJ, Ahmann DL, Jiang NS: Phase II study of tamoxifen in patients with disseminated malignant melanoma, Cancer Treatment Reports, 64: 199-201, 1980.
16. Coezy E, Borgna JL, Rochefort H: Tamoxifen and metabolites in MCF-7 cells: Correlation between binding to estrogen receptor and inhibition of cell growth, Cancer Res, 42: 317-323, 1982.
17. Lippman ME, Bolon G, Huff KK: The effects of estrogens and antiestrogens on hormone responsive human breast cancer in long-term tissue culture, Cancer Res, 36: 4595-4601, 1976.
18. Watts CKW, Murphy LC, Sutherland RL: Microsomal binding sites for nonsteroidal anti-estrogens in MCF-7 human mammary carcinoma cells, J Biol Chem, 259: 4223-4229, 1984.
19. Sudo K, Monsma FJ, Katzenellenbogen BS: Antiestrogen binding sites distinct from the estrogen receptor: Subcellular localization ligand specificity and distribution in tissues of the rat, Endocrinology, 112: 425-434, 1983.
20. Hing-Yat PL: Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase, Biochemical and Biophysical Research Communications, 118: 27-32, 1984.
21. O'B rian CA, Liskamp RM, Solomon DH, Weinstein B: Inhibition of protein kinase C by tamoxifen, Cancer Research, 45: 2462-2465, 1985.